drug
vismodegib
Marketedupdated 5mo agoby Genentech Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying vismodegib
- phase2Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- phase2Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- phase2A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
- phase2A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
- phase2Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
- EP1Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
- phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- phase1Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 11, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 15, 2028method-of-use (U-1825)US 92789612.2y
- Nov 11, 2028compositionUS 78883642.1y
News(1)
- Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancerHighlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell carcinoma (BCC).fiercebiotech · 4d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that